MCP
TVTX icon

Militia Capital Partners’s Travere Therapeutics TVTX Stock Holding History

Militia Capital Partners’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$588K Hold
15,400
– – 0.14% 150
2025
Q3 		$368K Hold
15,400
– – 0.09% 164
2025
Q2 		$228K Buy
+15,400
New +$255K 0.05% 170

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Militia Capital Partners's TVTX Position: Q4 2025 in Review

Militia Capital Partners held its Travere Therapeutics (TVTX) position steady in Q4 2025 at 15,400 shares worth $588K. The position accounts for 0.14% of the portfolio, ranked #150.

Militia Capital Partners first reported a position in TVTX in Q2 2025 and has held it in 3 quarters since. 278 funds tracked by Wall St. Rank hold TVTX as of Q4 2025.

  • Militia Capital Partners held 15,400 shares of Travere Therapeutics worth $588K as of Q4 2025.
  • Militia Capital Partners left its Travere Therapeutics share count unchanged in Q4 2025.
  • Travere Therapeutics made up 0.14% of Militia Capital Partners's portfolio in Q4 2025, its #150 holding.
  • Militia Capital Partners first reported a position in Travere Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 278 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2025.

Based on Militia Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.